Similar articles

• Risperidone for treatment-refractory major depressive disorder: a randomized trial.

  Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM. Mahmoud RA, et al. Ann Intern Med. 2007 Nov 6;147(9):593-602. doi: 10.7326/0003-4819-147-9-200711060-00003. Ann Intern Med. 2007. PMID: 17975181 Clinical Trial.
• Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.

  Pandina GJ, Revicki DA, Kleinman L, Turkoz I, Wu JH, Kujawa MJ, Mahmoud R, Gharabawi GM. Pandina GJ, et al. J Affect Disord. 2009 Nov;118(1-3):139-46. doi: 10.1016/j.jad.2009.02.019. Epub 2009 Mar 25. J Affect Disord. 2009. PMID: 19321206
• Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.

  Baune BT, Caliskan S, Todder D. Baune BT, et al. Hum Psychopharmacol. 2007 Jan;22(1):1-9. doi: 10.1002/hup.817. Hum Psychopharmacol. 2007. PMID: 17191266 Clinical Trial.
• Use of risperidone as augmentation treatment for major depressive disorder.

  Owenby RK, Brown LT, Brown JN. Owenby RK, et al. Ann Pharmacother. 2011 Jan;45(1):95-100. doi: 10.1345/aph.1P397. Epub 2010 Dec 28. Ann Pharmacother. 2011. PMID: 21189367 Review.
• Going beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical review.

  Maust DT, Oslin DW, Thase ME. Maust DT, et al. Am J Geriatr Psychiatry. 2013 Oct;21(10):973-86. doi: 10.1097/JGP.0b013e31826576cf. Epub 2013 Feb 6. Am J Geriatr Psychiatry. 2013. PMID: 23567381 Free PMC article. Review.